MOVEMENT PROFILE GEN Epidermal Growth Factor Receptor Exon 18 AND 19 IN PATIENTS WITH LUNG CANCER adenocarcinoma
ABSTRACT: BACKGROUND: Lung cancer is the leading cause of malignancy associated deaths worldwide. Adenocarcinoma of the lung is the most common subtype of lung cancer and has a lot of variants among the other types of lung cancer. It was correlated with certain patient characteristics, including female gender, Asian origin, and never-smoking history. Adenocarcinoma of the lung is reported to have an association with EGFR mutations especially on exon 18�21 that is found to be responsive to tyrosine kinase inhibitors (TKI). One of the most frequent mutations is located on exon 19. On the contrary, mutations on exon 18 are categorized as rare and uncommon. Study focusing on the profile of the mutation as the predictor for TKI is still limited. AIMS: To investigate the profile of EGFR gene mutations on exon 18 and 19 in patients with adenocarcinoma of the lung. METHODS: A cross sectional study using cytopathology samples that have been diagnosed by pathologists as an adenocarcinoma of the lung was performed. We used polymerase chain reaction and direct DNA sequencing to detect the mutation on exon 18 and 19. We analyzed the data and described the profile. RESULTS: Out of 30 samples, there were 14 mutations of EGFR gene, 7 mutations located on exon 18 and 2 mutations located on exon 19. The average age of patient with mutated EGFR gene on exon 18 and exon 19 were 61.70 and 67 years old, respectively. The comparison between 40-60 years old group and >60 years old group with mutation on exon 18 and 19 are 3:4 and 1:1. The percentages of male-female with mutation on exon 18 and 19 are 14.30%-85.70% and 50%-50%. CONCLUSIONS: Mutation on exon 18 commonly found in female with age >60 years old, meanwhile on exon 19, the percentages of both age and gender categories are equivalent. The prevalence of mutations of EGFR gene in adenocarcinoma of the lung on exon 18 is higher than exon 19.
